Diterpenoid tanshinones enhance CD8+ T-cell-mediated antitumor immunity in gastric cancer by suppressing ENO1 activity and glycolysis
Abstract
BackgroundSalvia miltiorrhiza Bunge contains bioactive tanshinones with antitumor activity, but whether diterpenoid tanshinones (DT) suppress gastric cancer by coupling glycolytic inhibition to CD8+ T-cell responses remains unclear. This study investigated the antitumor effects of DT and the contribution of the ENO1-lactate axis to tumor immune regulation.Materials and MethodsDT composition was characterized by ultra-performance liquid chromatography-high-resolution mass spectrometry. Antitumor activity was evaluated in a subcutaneous syngeneic MFC gastric cancer model in 615 mice, including CD8+ T-cell depletion and lactate-challenge experiments. Tumor-infiltrating immune cells were analyzed by flow cytometry, immunohistochemistry, and multiplex immunofluorescence. In gastric cancer cells, lactate production and extracellular acidification were measured using colorimetric and Seahorse assays. Network pharmacology, drug affinity responsive target stability, and cellular thermal shift assays were used to identify and assess candidate targets, followed by western blotting and enzyme-activity assays.ResultsDT suppressed tumor growth and increased intratumoral CD8+ T-cell infiltration, whereas CD8+ T-cell depletion attenuated its antitumor effect. DT reduced lactate production and glycolytic activity in gastric cancer cells and tumors. DARTS and CETSA supported target engagement between DT and ENO1. DT reduced ENO1 enzymatic activity and phosphoenolpyruvate levels without markedly changing ENO1 protein abundance. Exogenous lactate promoted tumor growth, while acidic culture conditions reduced CD8+ T-cell viability. Compared with the model group, DT alone increased the percentages of CD8+ and GZMB + cells and decreased the percentage of PD-1+ cells in tumor tissue.ConclusionDT restrains gastric tumor growth through an immunometabolic mechanism involving ENO1 inhibition, reduced glycolytic lactate production, and antitumor activity involving CD8+ T cells. These findings support further preclinical evaluation of DT and the ENO1-lactate axis in gastric cancer.
Related
- ATF3 Promotes Solasonine-Triggered Ferroptosis in Glioma Cells by Suppressing Glycolysis.
- A Tanshinone IIA Sulfonate Derivative Targets USP21 to Induce SCD1 Degradation, Suppressing NSCLC Metabolism and Enhancing Antitumor Immunity
- Medium chain fatty acid sensing receptor GPR84 limits antitumor immunity mediated by CD4 T cells in mice
- LKB1 promotes lung adenocarcinoma cell senescence by suppressing the O-GlcNAc glycosylation-mediated activation of telomerase
- Atractylenolide I ameliorates microglia-mediated cerebral ischemia/reperfusion injury by suppressing the TLR4/NF-κB/NLRP3 inflammasome axis
BibTeX
@article{guo2026diterpenoid,
title = {{Diterpenoid tanshinones enhance CD8+ T-cell-mediated antitumor immunity in gastric cancer by suppressing ENO1 activity and glycolysis}},
author = {Jianing Guo and Xiaochen Ni and Kaiyuan Zhang and Chuhang Wang and Wei Fan and Tao Jiang and Guangji Zhang},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1925187},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1925187},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Diterpenoid tanshinones enhance CD8+ T-cell-mediated antitumor immunity in gastric cancer by suppressing ENO1 activity and glycolysis
AU - Jianing Guo
AU - Xiaochen Ni
AU - Kaiyuan Zhang
AU - Chuhang Wang
AU - Wei Fan
AU - Tao Jiang
AU - Guangji Zhang
PY - 2026
DA - 2026/11/06
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1925187
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1925187
AB - BackgroundSalvia miltiorrhiza Bunge contains bioactive tanshinones with antitumor activity, but whether diterpenoid tanshinones (DT) suppress gastric cancer by coupling glycolytic inhibition to CD8+ T-cell responses remains unclear. This study investigated the antitumor effects of DT and the contribution of the ENO1-lactate axis to tumor immune regulation.Materials and MethodsDT composition was characterized by ultra-performance liquid chromatography-high-resolution mass spectrometry. Antitumor activity was evaluated in a subcutaneous syngeneic MFC gastric cancer model in 615 mice, including CD8+ T-cell depletion and lactate-challenge experiments. Tumor-infiltrating immune cells were analyzed by flow cytometry, immunohistochemistry, and multiplex immunofluorescence. In gastric cancer cells, lactate production and extracellular acidification were measured using colorimetric and Seahorse assays. Network pharmacology, drug affinity responsive target stability, and cellular thermal shift assays were used to identify and assess candidate targets, followed by western blotting and enzyme-activity assays.ResultsDT suppressed tumor growth and increased intratumoral CD8+ T-cell infiltration, whereas CD8+ T-cell depletion attenuated its antitumor effect. DT reduced lactate production and glycolytic activity in gastric cancer cells and tumors. DARTS and CETSA supported target engagement between DT and ENO1. DT reduced ENO1 enzymatic activity and phosphoenolpyruvate levels without markedly changing ENO1 protein abundance. Exogenous lactate promoted tumor growth, while acidic culture conditions reduced CD8+ T-cell viability. Compared with the model group, DT alone increased the percentages of CD8+ and GZMB + cells and decreased the percentage of PD-1+ cells in tumor tissue.ConclusionDT restrains gastric tumor growth through an immunometabolic mechanism involving ENO1 inhibition, reduced glycolytic lactate production, and antitumor activity involving CD8+ T cells. These findings support further preclinical evaluation of DT and the ENO1-lactate axis in gastric cancer.
SN - 1663-9812
ER -